Login to Your Account



FDA approves Gilead's HCV combo, Harvoni

By Michael Fitzhugh
Staff Writer

Friday, October 10, 2014

Gilead Sciences Inc. won FDA approval to market Harvoni, the first oral therapy for people with genotype 1 hepatitis C virus (HCV) to eliminate the need for both interferon and ribavirin.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription